Hyperfunctioning papillary thyroid carcinoma – a case report and literature review

References

• Haugen BR, Alexander EK, Bible KC, et al. 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26(1):1–133.
   PubMed Web of Science ®Google Scholar
• Liu J, Wang Y, Da D, et al. Hyperfunctioning thyroid carcinoma: a systematic review. Mol Clin Oncol. 2019;11(6):535–550.
   PubMed Web of Science ®Google Scholar
• Mirfakhraee S, Mathews D, Peng L, et al. A solitary hyperfunctioning thyroid nodule harboring thyroid carcinoma: review of the literature. Thyroid Res. 2013;6(1):7.
   PubMedGoogle Scholar
• Manmadharao V, Kirankumar G, Jayaramudu Y, et al. A rare case of papillary carcinoma of thyroid with hyperthyroidism. Jemds. 2015;04(10):1694–1698.
   Google Scholar
• Pazaitou-Panayiotou K, Michalakis K, Paschke R. Thyroid cancer in patients with hyperthyroidism. Horm Metab Res. 2012; 44(4):255–262.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. Thyroid carcinoma (Version 1.2023) 2023. [April, 2023].
   Google Scholar
• Fan CY, Huang WY, Lin CS, et al. Risk of second primary malignancies among patients with prostate cancer: a population-based cohort study. PLoS One. 2017;12(4):e0175217.
   PubMed Web of Science ®Google Scholar
• Lee ES, Kim Jh Fau- Na DG, Na Dg Fau- Paeng JC, et al. Hyperfunction thyroid nodules: their risk for becoming or being associated with thyroid cancers. Korean J Radiol. 2013;14(4):643–652.
   Google Scholar
• Lau LW, Ghaznavi S, Frolkis AD, et al. Malignancy risk of hyperfunctioning thyroid nodules compared with non-toxic nodules: systematic review and a meta-analysis. Thyroid Res. 2021; 14(1):3.
   PubMed Web of Science ®Google Scholar
• Schenke SA, Kreissl MC, Grunert M, et al. Distribution of functional status of thyroid nodules and malignancy rates of hyperfunctioning and hypofunctioning thyroid nodules in Germany [verteilung der szintigraphischen funktionalität von schilddrüsenknoten und malignitätsrate von hyperfunktionellen und hypofunktionellen schilddrüsenknoten in deutschland. Nuclear Med. 2022;61(5):376–384.
   Google Scholar
• Song X, Luo Z, Sun H, et al. Systematic review and meta-analysis of the diagnostic value of radionuclide imaging for thyroid nodules. Gland Surg. 2021;10(12):3351–3361.
   PubMed Web of Science ®Google Scholar
• Erdoğan MF, Anil C, Ozer D, et al. Is it useful to routinely biopsy hot nodules in iodine deficient areas? J Endocrinol Invest. 2003;26(2):128–131.
   PubMed Web of Science ®Google Scholar
• Russ G, Bonnema SJ, Erdogan MF, et al. European thyroid association guidelines for ultrasound malignancy risk stratification of thyroid nodules in adults: the EU-TIRADS. Eur Thyroid J. 2017;6(5):225–237.
   PubMed Web of Science ®Google Scholar
• Kim EK, Park CS, Chung WY, et al. New sonographic criteria for recommending fine-needle aspiration biopsy of nonpalpable solid nodules of the thyroid. AJR Am J Roentgenol. 2002;178(3):687–691.
   PubMed Web of Science ®Google Scholar
• Lim H, Devesa SS, Sosa JA, et al. Trends in thyroid cancer incidence and mortality in the United States, 1974–2013. JAMA. 2017;317(13):1338–1348.
   Google Scholar
• Qiu ZL, Shen Ct Fau- Luo Q-Y, Luo QY. Clinical management and outcomes in patients with hyperfunctioning distant metastases from differentiated thyroid cancer after total thyroidectomy and radioactive iodine therapy. Thyroid: official journal of the American Thyroid Association. 2015;25(2):229–237.
   Google Scholar
• Kondo T, Ezzat S Fau- Asa SL, Asa SL. Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nature Rev. Cancer. 2006;6(4):292–306.
   Google Scholar
• Acuña-Ruiz A, Carrasco-López C, Santisteban P. Genomic and epigenomic profile of thyroid cancer. Best Pract Res Clin Endocrinol Metab. 2023;37(1):101656.
   PubMed Web of Science ®Google Scholar
• Tang KT, Lee CH. BRAF mutation in papillary thyroid carcinoma: pathogenic role and clinical implications. J Chin Med Assoc. 2010; 73(3):113–128.
   PubMed Web of Science ®Google Scholar
• Sobrinho-Simões M, Máximo V, Fau- Rocha AS, et al. Intragenic mutations in thyroid cancer. Endocrinology and Metabolism Clinics of North America. 2008;37(2):333–viii.
   Google Scholar
• Parma J, Van Sande J, Fau- Swillens S, et al. Somatic mutations causing constitutive activity of the thyrotropin receptor are the major cause of hyperfunctioning thyroid adenomas: identification of additional mutations activating both the cyclic adenosine 3',5'-monophosphate and inositol phosphate-Ca2+ Cascades. Molecular Endocrinology (Baltimore, Md.). 1995;9(6):725–733.
   Google Scholar
• Parma J, Duprez L, Fau- Van Sande J, et al. Somatic mutations in the thyrotropin receptor gene cause hyperfunctioning thyroid adenomas. Nature. 1993;365(6447):649–651.
   Google Scholar
• Shinkai S, Ohba K, Kakudo K, et al. Hyperfunctioning papillary thyroid carcinoma with a BRAF mutation: the first case report and a literature review. Eur Thyroid J. 2021;10(3):262–267.
   PubMed Web of Science ®Google Scholar
• Skowronska A, Milczarek-Banach J, Wiechno W, et al. Accuracy of the European thyroid imaging reporting and data system (EU-TIRADS) in the valuation of thyroid nodule malignancy in reference to the post-surgery histological results. Pol J Radiol. 2018;83:e579–e586.
   PubMed Web of Science ®Google Scholar
• Chang DJ, Lippman SS, Semrad AM, et al. Prevalence of suspicious ultrasound features in hot thyroid nodules. Fed Pract. 2018; 35(Suppl 4):S46–S48.
   PubMedGoogle Scholar
• Frates Mc Fau- Benson CB, Benson Cb Fau- Charboneau JW, Charboneau Jw Fau- Cibas ES, et al. Management of thyroid nodules detected at US: society of radiologists in ultrasound consensus conference statement. Radiology. 2005;237(3):794–800.
   Google Scholar